Study Design

Study participants will attend at least 12 study visits over a period of approximately 10 months. Study participation is made up of three types of study visits:

Screening Visit(s)

at least 1 visit

During this time, the study doctor and study staff conduct a number of tests, assessments, and procedures to determine if potential participants are fully eligible to participate.

During these visits, study participants will receive their assigned study drug (investigational drug or placebo). In addition, the study doctor will continue to conduct study-related tests, assessments, and procedures to monitor the health of study participants and to gather data to help determine the effects (if any) of the investigational drug.

Follow-up Visit

1 visit

Study participants will return to the study location four weeks after their final Study Treatment Visit for final study-related tests, assessments, and procedures.

Study Treatment Groups

Study participants will be randomly assigned to one of three study treatment groups.

Why is there a placebo group?

The placebo group plays an important role in this clinical research study, because it is the best way for researchers to measure the effects of the investigational drug on Parkinson’s disease. PROSEEK is a double-blind study, which means neither the study participant nor the study doctor will know who is receiving the investigational drug and who is receiving the placebo.

ABOUT PROSEEK

AM I ELIGIBLE?